



In a major victory for public health, [Congress passed](#) the Mainstreaming Addiction Treatment Act (MAT Act) at the end of 2022.

What does this mean for you as a Healthcare Provider?

[Prescribing buprenorphine](#) for opioid use disorder just got easier. The [DATA-Waiver \(X-Waiver\)](#) Program was eliminated on December 29, 2022, with [President Biden's signing of the Consolidated Appropriations Act of 2023](#), which contains the Mainstreaming Addiction Treatment Act (MAT Act). Now, practitioners with a current Drug Enforcement Administration (DEA) registration may prescribe buprenorphine for opioid use disorder if permitted by [state law](#).

New Training Requirements Issued for DEA Registration

[New training requirements](#) for DEA registration were also introduced in the Omnibus bill, but will not go into effect until June 21, 2023. The requirements are summarized as at least 8 hours of training on the treatment and management of patients with opioid use disorder. The [DEA](#) and [SAMHSA](#) will provide further guidance on these requirements in the coming months.

Resources to Help Spread the Word

- Check out our victory video at: ppls.ac/MATActVictoryVid
- Share this one-pager: ppls.ac/MATActHCP
- Share our community-focused one-pager: ppls.ac/MATActComm
- Review the Substance Abuse and Mental Health Services Administration's official announcement about this change: ppls.ac/MATActSAMHSA